Fernando is CEO of Stratence Partners, a well-known global consulting, systems and outsourcing company, and has more than 25 years of experience helping organizations worldwide, optimizing Strategies, enhancing Commercial Effectiveness, and implement­ing successfully Pricing Excellence. Fernando is a recognized expert in producing tan­gible economic results through pragmatic “Short Term Solutions” and delivering long term visions as “Sustainable World-Class Capabilities”. Fernando is a frequent chairman, VIP workshop owner, and speaker at leading conferences globally, and regularly edits expert articles and whitepapers. His professional career highlights include roles as CEO, CSO, VP, GM, Marketing, Sales, Operations, and Program & Project Manager at leading companies such as Proudfoot (US), Matrix (UK), PwC (Spain), McKinsey (Portugal), IIC (Belgium), and IMP (France). Fernando has a DipHE in industrial engineering from the Science School of Cachan (Paris), a BScIT from the ESCP (Paris), an MBA from the EAP (Oxford), and he is finishing his PhD in strategy & organization at the Swiss Manage­ment Center (Zurich). He speaks French, English, Spanish, Portuguese, Galician, and Catalan fluently and enjoys international projects to continuously improve his Italian, German, and Chinese.

Lidia is qualified in Medicine with a postgraduate education in Psychiatry. She obtained an EMBA from Antwerp Management School. She has almost 20 years of experience in the pharmaceutical industry with regional and country operational management experience. She has a consistent record of business turnarounds, delivering substantial growth, top ranking market share positions and strong financial results as measured by multi-million-dollar P&Ls under responsibility. Successful results were recognized through promotions from sales rep, progressively increasing marketing and sales roles to Franchise Head. For the last 2 years, Lidia has been working in Health & Value, being responsible for innova­tive contracting, insight strategy, health economics modelling, partnership management, payer excellence, and patient access programs. Her success is driven by a strategic view, with a sharp focus on what matters and the ability to identify customer/stakeholder needs.

Dražen is qualified in Medicine with a postgraduate education in bioscience and a MBA degree. He has 15 years of experience in pharmaceutical industry in almost all fields. Most of Dražen’s professional experience was in the field of oncology, which gave him a valuable experience of overcoming hurdles in access to innovation in demanding envi­ronment. He is currently Market Access Director responsible for leading Market Access team and establishing access cross-functional collaboration in Roche Croatia.

Michele Siccardi is the Head of Program Realization Global Market Access for Takeda Pharmaceutical International in Zurich. In his current role, he drives Market Access above-brand strategic initiatives and programs that enable Takeda to transform towards a customer-centric specialty care provider. Before joining Takeda, Michele spent more than 12 years in the Industry developing significant experience in Strategic Planning, Com­mercial Excellence and Business Operations for both large (J&J and Covidien / Medtronic) and mid-size players (Mallinckrodt Pharmaceutical). Michele holds a full-time MBA with specialization in Strategy and Finance from Schulich School of Business (York University, Toronto) and a Master of Science in Economics from LUISS University in Rome.

After studying Business-Law, Matthias Diessel completed a trainee-program and worked as a consultant for contracts and analysis at the AOK Berlin (SHI). He followed that up by working at the vfa, Ranbaxy, easyApotheke, and Pro Geneirka in the field of Market Access and Governmental Affairs – accompanied by an Executive MBA program at the ESCP Europe. Currently, he holds the position as Director Market Access & GA at Teva.

Gundula Koblmiller has worked in the Pharmaceutical Industry since 1991 within differ­ent companies and positions covering Market Access, Launch Excellence, Pre-Launch, Sales, and Marketing at e.g. GSK, Byk/Altana/Nycomed, Mundipharma, and Teva. Her workplace was in Austria, but also worked within project management in Germany and internationally. She has a Master of Science in health management and pharmamanage­ment (Danube University of Krems) and also holds certificates in Pharmareferent, Mar­keting, Market Access & Reimbursement, Coaching, and Consulting. At Teva, she was involved in Market Access and Pre-Launch Activities of generic and original products and knows about cross-functional internal as well as external challenges.

Fabrizio earned his PhD and a master’s in health economics (Rome, Stockholm, York). He also obtained a master’s in economic journalism. He has experience as a professor of health economics, market access consultant, and a registered journalist. His prior experience includes: AIFA member, regional HTA Committees member, director at the Ministry of Health (appointed), general manager and vice president of GSK Foundation Italy and of Angelini Foundation, several director roles in pharmaceutical industries, sec­ondments in UK and US. He is also the past director of several magazines on healthcare and pharma. Adding to that, he is a past member of Farmindustria, Assobiotech, CEN­SIS, EFPIA, Federfarma. Fabrizio is a board member of the Italian Society of Pharmaco­economics and Ethicals and the Italian society of Healthcare studies. He is a chairman and speaker at national and international conferences and congresses, while also being an author of more than 700 articles and 7 books.

Simon is the Senior Director of Global Market and Pricing at Ipsen. He covers market access and health economic evidence planning for pipeline products and leads pricing and reimbursement due diligence for in-licensed assets across Ipsen’s franchises of on­cology, endocrinology, and neurosciences. He also leads global market access for Ipsen’s Increlex ® brand. He has previously held various senior roles in international pharma consulting including at IMS Consulting Group (now QuintilesIMS) and Pope Woodhead Associates (now part of Huron) where he led global assignments in market access, launch excellence, and forecasting in speciality and rare disease medicines. Previously, he was a Postdoctoral Fellow in Technology Economics at London Business School and holds a PhD in cell biology (UCL) and a Diploma in Public Affairs (CIPR).

Jörg Mahlich is a health economist for Janssen, Pharmaceutical Companies of Johnson and Johnson. Prior to his current position, he was an economist for the Austrian Eco­nomic Chamber. He has also been a lecturer at the University of Vienna and Fachhoch­schule Wien. He received his diploma in economics from Christian-Albrechts-Universitat zu Kiel and a Ph.D in economics in 2000 at the University of Vienna.

Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in the Lyon School of Medicine, France where he also gained a Master’s Degree in Medical and Biological Sciences, including Pharmacology, Psychology, and Medical Statistics. Prior to this, he received an MBA from the Superior School of Business and Administration and Economics (ESSEC) in Paris. He then worked as a Clinician, practicing General Medicine as well as being a Registrar in Emergency Medicine and Intensive Care in a University Teaching Hospital in Lyon, France. He started his Pharmaceutical Career in Pfizer Cen­tral Research as a Clinical Research Physician and then joined the Outcomes Research Division where he held a number of successive positions in the Product Development Group and the Medical division. He subsequently joined Health-Economics and Out­comes Research at Novartis and Shire. Patrick has extensive experience in developing and implementing Health Economic strategies to support developmental compounds in a number of therapeutic areas, including Cardiovascular, Urology, Anti-Virals, Dermato- Immunology, and Rare Disesases, leading the value identification and demonstration efforts for Market Access and Health Technology Assessment from a Global perspective. As such, he is leading the development of Patient Reported Outcomes tools, Health- Economic and Budget-Impact models, Value Dossiers and Real World Evidence. Patrick has a number of publications in the area of Health-Economics and Outcomes Research. His main interests are in health-economic modelling methods and applications as well as patient-reported outcomes and decision-making.

Axel Boehnke is the director of market access & reimbursement DACH for Intercept, and member of the leadership team in the DACH region. He´s fully responsible for all market access aspects (from dossier to price negotiation), patient access as well early evidence planning as well as actions to accelerate access to patients in Liver Disease / Hepatology. His experience in this area of work has allowed him to develop a sophisticated AMNOG skill set. Axel has also in-depth knowledge and expertise in the specialized business, like Immunology, (ultra) orphan business etc. Also in therapeutic mass markets like cardio­vascular or Osteoporosis. He worked at one of the biggest German Payers and is Health Economist (University of Cologne) by education. In addition, he holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access and the German Society of Health Economics. He heads conferences on Market Access topics regarding AMNOG, pricing and Reimburse­ment. He published various articles on topics like benefit assessment, Market Access, Healthcare-system issues and disease awareness.

Massimo is VP at Stratence Partners, a well-known global consulting, systems, and out­sourcing company, and has numerous years of experience helping the organizations worldwide, optimizing Strategies, enhancing Commercial Effectiveness and implement­ing successfully Pricing Excellence. Massimo is a dynamic, pro-active, pragmatic, high performing senior executive, having successfully developed and led organizations and multifunctional teams to achieve outstanding results in international leadership posi­tions. A skilful communicator with highly developed interpersonal skills and ability to engage, influence, develop and motivate both individuals and teams across cultures and functions, shaping the strategy and driving behavioural change in several regions and countries. His professional career highlights include roles as Senior Commercial VP, VP and Portfolio & Supply Chain Director, and Technical Director at leading companies such as PGT Healthcare, Teva Pharmaceuticals, Chiesi Farmaceutici, and Nicim. Massimo has a bachelor’s degree in electronic engineering cum laude from the Università Statale degli Studi (Genova - IT), an Executive MBA from Bocconi SDA (Milan). He fluently speaks Italian, English, and enjoys international Projects to continuously improve his French, Spanish, and Hebrew.

Hassan Bruneo is currently Associate Director Market Access & Policy at Alnylam, based in Zug. He is responsible for Strategic Pricing for the EuCan region and Market Access Head for France, Italy, and the Nordic Region. He joined Alnylam in July 2017, coming from Biogen where he worked in the EU+ Market Access and Strategic Pricing team. He received his degree in biomedical engineering, from the Polytechnic of Milan, Italy in 2007. In the same year he started his business education in consultancy specializing in life sciences projects with public bodies (e.g. health performance improvement for public and private hospitals) and private institutions. His consulting work focused on designing commercial strategies (including international pricing and reimbursement), in order to maximize the monetization of the innovation for pharmaceutical companies. His current experience in Biogen is focusing on keeping the current value of the MS portfolio maintaining an open dialogue with payers and external stakeholders in order to partner with policy makers to balance the need for feeding innovation and affordability. Hassan also contributed in training sessions, workshops and publications during his consultancy experience.

Tomasz is a Regional Principal for IQVIA Consulting, covering CEE, Russia, and CIS and responsible for strategic projects such as Launch Excellence, Market Access, Pricing, and Portfolio and Geo Expansion. Before joining IQVIA, he worked as the Head of Healthcare Practice EMEA for Kaiser Associates in London. Tomasz has worked closely with Global, Regional, and Local Pharma companies, across the US, Europe, Russia and CIS. He is a Speaker at Global and European Conferences on, amongst others: Biosimilars, Pric­ing and Market Access, Real World Evidence and he is also an Author of White Papers and Publications, amongst others, “Delivering on the Potential of Biosimilar Medicines”. Tomasz holds MA degree from University of Oxford.